Quantcast

FDA approves ViiV Healthcare’s dolutegravir tablet for children living with HIV

ViiV Healthcare Friday said that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, used combined with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain young patients.

Read more

GSK to make an equity investment of $250 million in Vir Biotechnology to tackle COVID-19

GlaxoSmithKline and Vir Biotechnology have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19, in which GSK will make an equity investment in Vir of $250 million, to gain access to Vir’s technology.

Read more

Colorectal Cancer Therapeutics: Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront

Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront

Read more